Since the beginning of the pandemic, researchers around the world have sought a cure for COVID-19. And while the COVID-19 vaccine is the best way to prevent illness, there is still a shortage of treatments for infected people. A new breakthrough study of UM has shown that it blocks or reduces intracellular SARS-CoV2 infection, with several candidate drugs already in use for other purposes (one dietary supplement). Including) has been clarified.
Recently published studies Minutes of the National Academy of SciencesUses image analysis of human cell lines using artificial intelligence infection With a new coronavirus. NS cell Before or after the viral infection, treatment and screening with over 1,400 individual FDA-approved drugs and compounds resulted in 17 potential hits.10 of those hits were newly recognized and 7 were previously identified drag A diversion study involving remdesivir, one of the few FDA-approved therapies for COVID-19 in inpatients.
“Traditionally, the drug development process takes 10 years, but not 10 years,” said Dr. Jonathan Sexton, an assistant professor of internal medicine at UM Medical School and one of the senior authors of the treatise. .. “The treatments we have discovered are well-positioned for Phase 2 clinical trials because their safety has already been established.”
The team examined 17 candidate compounds in several types of cells, including stem cell-derived human lung cells, to mimic SARS-CoV2 infection in the respiratory tract. Nine showed antiviral activity at reasonable doses containing lactoferrin. Lactoferrin is a protein found in human breast milk that is also available in stores as a dietary supplement derived from milk.
“Lactoferrin has been found to be surprisingly effective in preventing infections and is more effective than anything else we have observed,” says Sexton. He adds that early data suggest that this efficacy extends to new variants of SARS-CoV2, including highly contagious delta mutants.
The team will launch soon Clinical trial Analysis of compounds to determine viral load and ability to reduce inflammation in SARS-CoV2-infected patients.
The trial has been added to the list of ongoing studies of promising reusable drugs. During the pandemic process, Sexton said other drug repositioning studies have identified a variety of compounds with potential efficacy against SARS-CoV2. “The results seem to depend on the cellular system used,” he said.
“But new consensus is emerging about a subset of drugs, which are the highest priorities for clinical translation. Most of these are fully expected to not work in humans, but they do. I expect that there will be. “
Amazing discoveries about certain drugs and COVID
Notably, the UM study also identified a class of compounds called MEK inhibitors, usually prescribed for the treatment of cancer, that appear to exacerbate SARS-CoV2 infection. This finding reveals how the virus spreads between cells.
“People who receive chemotherapy are already at risk from a weakened immune response, and we need to investigate whether some of these drugs exacerbate the progression of the disease,” said Sexton. ..
The next step is to use electronic health records to see if COVID-19 results are poor for patients taking these medications.
This work is one of the first major discoveries to emerge from the new UM Drug Diversion Center (CDR), which was established just in November 2019 when the pandemic began. The Michigan Institute for Clinical Health (MICHR) has set up a center in collaboration with campus-wide partners to find potential treatments for thousands of human illnesses for which there is no cure.
“Diverting existing therapeutic interventions in the clinical setting can significantly reduce discovery-to-clinical use time, including a documented safety profile, reduced regulatory burden, and significant cost savings. There are many benefits, “says George A. Mashour, MD, Ph.D. .. , Co-Director of MICHR and Founder / Executive Sponsor of CDR.
Carmen Mirabelli et al, morphological cell profiling of SARS-CoV-2 infection, identifies drug repositioning candidates for COVID-19. PNAS (2021). DOI: 10.1073 / pnas.2105815118
University of Michigan
Quote: By research, SARS- in cells obtained on August 19, 2021 from https: //medicalxpress.com/news/2021-08-drugs-sars-cov2-cells.html (August 19, 2021) An existing drug found that can kill CoV2
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.
Study finds existing drugs that can kill SARS-CoV2 in cells Source link Study finds existing drugs that can kill SARS-CoV2 in cells